3ewc Citations

Structural and metabolic specificity of methylthiocoformycin for malarial adenosine deaminases.

Biochemistry 48 9618-26 (2009)
Cited: 20 times
EuropePMC logo PMID: 19728741

Abstract

Plasmodium falciparum is a purine auxotroph requiring hypoxanthine as a key metabolic precursor. Erythrocyte adenine nucleotides are the source of the purine precursors, making adenosine deaminase (ADA) a key enzyme in the pathway of hypoxanthine formation. Methylthioadenosine (MTA) is a substrate for most malarial ADAs, but not for human ADA. The catalytic site specificity of malarial ADAs permits methylthiocoformycin (MT-coformycin) to act as a Plasmodium-specific transition state analogue with low affinity for human ADA [Tyler, P. C., Taylor, E. A., Frohlich, R. G. G., and Schramm, V. L. (2007) J. Am. Chem. Soc. 129, 6872-6879]. The structural basis for MTA and MT-coformycin specificity in malarial ADAs is the subject of speculation [Larson, E. T., et al. (2008) J. Mol. Biol. 381, 975-988]. Here, the crystal structure of ADA from Plasmodium vivax (PvADA) in a complex with MT-coformycin reveals an unprecedented binding geometry for 5'-methylthioribosyl groups in the malarial ADAs. Compared to malarial ADA complexes with adenosine or deoxycoformycin, 5'-methylthioribosyl groups are rotated 130 degrees . A hydrogen bonding network between Asp172 and the 3'-hydroxyl of MT-coformycin is essential for recognition of the 5'-methylthioribosyl group. Water occupies the 5'-hydroxyl binding site when MT-coformycin is bound. Mutagenesis of Asp172 destroys the substrate specificity for MTA and MT-coformycin. Kinetic, mutagenic, and structural analyses of PvADA and kinetic analysis of five other Plasmodium ADAs establish the unique structural basis for its specificity for MTA and MT-coformycin. Plasmodium gallinaceum ADA does not use MTA as a substrate, is not inhibited by MT-coformycin, and is missing Asp172. Treatment of P. falciparum cultures with coformycin or MT-coformycin in the presence of MTA is effective in inhibiting parasite growth.

Reviews - 3ewc mentioned but not cited (1)

  1. Enzymatic Transition States and Drug Design. Schramm VL. Chem Rev 118 11194-11258 (2018)

Articles - 3ewc mentioned but not cited (4)



Reviews citing this publication (3)

  1. Purine and pyrimidine pathways as targets in Plasmodium falciparum. Cassera MB, Zhang Y, Hazleton KZ, Schramm VL. Curr Top Med Chem 11 2103-2115 (2011)
  2. Moonlighting adenosine deaminase: a target protein for drug development. Cortés A, Gracia E, Moreno E, Mallol J, Lluís C, Canela EI, Casadó V. Med Res Rev 35 85-125 (2015)
  3. Transition-state inhibitors of purine salvage and other prospective enzyme targets in malaria. Ducati RG, Namanja-Magliano HA, Schramm VL. Future Med Chem 5 1341-1360 (2013)

Articles citing this publication (12)